Novartis taps immuno-oncology partner BeiGene for TIGIT drug
pharmaphorum
DECEMBER 21, 2021
Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.
Let's personalize your content